Development and Clinical Applications of Theranostic Radiopharmaceuticals in Iran
Member States Side Events
In the Islamic Republic of Iran, cancer is the third leading cause of death. In 2018, about 110 000 cancer cases were reported, resulting in the loss of about 56 000 lives. To enhance the country’s effective clinical utilization of new generation theranostic radiopharmaceuticals at the national level, ongoing efforts focus on strengthening capacity in the areas of research and development as well as production and quality control of new generation theranostic radiopharmaceuticals, such as PET-based radiopharmaceuticals, and therapeutic peptide-based radiopharmaceuticals through different national/international projects. This event is organized by the Islamic Republic of Iran.
This event will be held on Tuesday, 26 September 2023, from 10.00 a.m. to 11.30 a.m. in Conference Room M7, M Building, ground floor.